



Majrity	FSRPGLPVEYLQVPSXS MGRDI KVQFQSGGXNS PAVYLLDGLRAQDDYNGWDI NT PAFEWYIYQSGLSVXMPVGGQSSFYS	
	10 20 30 40 50 60 70 80	
Mkan 85B	FSRPGLPVEYHQVPSAAMGRSI KVQFQSGGDNS PAVYLLDGLRAQDDYNGWDI NT PAFEWYIYQSGLSVI MPVGGQSSFYS	80
Mtb 85A	FSRPGLPVEYLQVPSPS MGRDI KVQFQSGGANS PALYLLDGLRAQDDFS GWDI NT PAFEWYDQSGLSVVM PVGGQSSFYS	80
Mtb 85B	FSRPGLPVEYLQVPSPS MGRDI KVQFQSGGNS PAVYLLDGLRAQDDYNGWDI NT PAFEWYIYQSGLSI VMPVGGQSSFYS	80
Mtb 85C	FSRPGLPVEYLQVPSAS MGRDI KVQFQGGG-- PHAVYLLDGLRAQDDYNGWDI NT PAFEEYIYQSGLSVI MPVGGQSSFYT	78
Majrity	DWYXPACGKAGCQT YKWET FLTSEL PQWLXANRS VKPTGSAAVGLSMAGSSALI LAAYHPQQFIYAGLSLXLLDPSQGMG	
	90 100 110 120 130 140 150 160	
Mkan 85B	DWYSPACGKAGCTTYKWET FLTSEL PQWLSANRSVKPTGSAAVGI SMAGSSALI LSVYHPQQFIYAGLSLALMDPSQGMG	160
Mtb 85A	DWYQPACGKAGCQT YKWET FLTSEL PGWLQANRHVKPTGSAAVGLSMAASSALT LAI YHPQQFVYAGAMSGLLDPSQAMG	160
Mtb 85B	DWYSPACGKAGCQT YKWET FLTSEL PQWLSANRAVKPTGSAAI GLSMAGSSAMI LAAYHPQQFIYAGLSALLDPSQGMG	160
Mtb 85C	DWYQPSQSNQGNITYKWET FLTREMPAWLQANKSVSPTGNAAVGLSMSGGSALI LAAYYPQQFPYAASLSGFLNPSQGMG	158
Majrity	PXLI GLAMGDAGGYKASDMWGPSS DPAWQRNDPXLQI PKLVANNTRLWVYCGNGTPSXLGGANI PAXFLEXFVRSSNLKF	
	170 180 190 200 210 220 230 240	
Mkan 85B	PSLI GLAMGDAGGYKASDMWGPSS DPAWQRNDPSLHI PELVANNTRLWI YCGNGTPSXLGGANVPAEFLENFVRSSNLKF	240
Mtb 85A	PTLI GLAMGDAGGYKASDMWGPKE DPAWQRNDPLL NVGKLI ANNTRVWVYCGNGKPSDLGGNNLPAKFLEGFVRTSNI KF	240
Mtb 85B	PSLI GLAMGDAGGYKAADMWGPSS DPAWERNDPTQQI PKLVANNTRLWVYCGNGT PNLGGANI PAEFLENFVRSSNLKF	240
Mtb 85C	PTLI GLAMNDSGGYNANSMMWGPSS DPAWKRNDPMVQI PRLVANNTRI WVYCGNGT PSDLGGDNI PAKFLEGLTLRTNQT	238
Majrity	QDAYNAAGGHNVFN FPPNGT HSWEYWGAQLNAMKGDLSL-GATX---XX---X	
	250 260 270 280 290	
Mkan 85B	QDAYNAAGGHNAVFN LDANGT HSWEYWGAQLNAMKGDLSL-GAR	286
Mtb 85A	QDAYNAGGGHNGVFD FPDST HSWEYWGAQLNAMKPDLQRAL-GATPNTGPAPQGA	295
Mtb 85B	QDAYNAAGGHNAVFN FPPNGT HSWEYWGAQLNAMKGDLSL-GAG	285
Mtb 85C	RDTYAADGGRNGVFN FPPNGT HSWPYWNEQLVAMKADI QHVLNGATPPAAPAAPAA	294
	H149	

Supplemental Figure 1. Alignment of amino acid sequences of the immunodominant epitopes of the fibronectin binding proteins of the antigen 85 complex of Mtb and *M. kansasii*. The antigen 85 (Ag85) complex of three proteins with Ag85A, Ag85B and Ag85C of Mtb were compared by alignment with Ag85B of *M. kansasii* with ClustalW. Magenta and green boxed residues are pep8 (aa 61-69) and pep9 (aa 62-70) epitopes for polyfunctional CD4+ T cell-activation in rBCG85B/DNA85B-immunized H2d BALB/c or H2b/d CB6F1 mice. Blue boxed residues are H149 epitopes (aa 241-255) for CD4+ T cell-activation on the Ag85B in the immunized H2b C57BL/6 or H2b/d CB6F1 mice.

A




B




Supplemental Figure 2. Western blot of expression of Mkan85B protein by rBCG and in 293T transfectants.

(A) rBCG-Mkan85B, rBCG-Mbov85B, and BCG were grown in Middlebrook 7H9 medium supplemented 10% ADC, 0.0625% Tween80, and 100 mg/mL kanamycin. The bacterial cells were centrifuged then lysed, and SDS solubilized lysate was run on an SDS-containing polyacrylamide gel, and blotted. The expression of Ag85B was detected using anti-Ag85B polyclonal antibody (Abcam, Cambridge, UK). Lane 1, solubilized BCG lysate; Lane 2, solubilized rBCG-Mbov85B lysate; Lane 3, solubilized rBCG-Mkan85B lysate. Graph shows densitometric value of Ag85B. Western blot represents three independent experiments. **, $p < 0.01$; one-way ANOVA test. Error bars represent SEM. (B) Expression of Ag85B protein in p3H-Mkan85B and plasmid DNA85B transfected 293T cells. p3H-Mkan85B (lane 4), Plasmid DNA85B (lanes 2), or control p3H vector lacking Mkan85B (lane 5 and 6), control VRC8400 vector lacking Mkan85B (lane 1 and 2) were transfected into 293T cells as described in Materials and Methods and analyzed by SDS-PAGE, and Western Blotting, as described above. Lane 7, recombinant Mtb85B protein. Western blot represents three independent experiments.



Supplemental Figure 3. Immunization schedule. Mice were immunized with BCG vaccine, rBCG-Mkan85B or rBCG-Mbov85B at a concentration of 4×10^6 CFU or 0.1 mg of bacilli i.d., and 100 μg of plasmid DNA or control DNA in saline i.m. three times.



Supplemental Figure 4. Comparison of immunogenicity between rBCG-Mkan85B and rBCG-Mbov85B. CB6F1 mice were immunized by priming with rBCG-Mkan85B and boosting with plasmid DNA-Mkan85B (rBCG-Mkan85B/DNA-Mkan85B) or rBCG-Mbov85B and boosting with plasmid DNA-Mbov85B (rBCG-Mbov85B/DNA-Mbov85B). We studied polyfunctional CD4⁺ or CD8⁺ T cells after immunization followed by in vitro restimulation with pep8 (left panel) or pep9 (right panel). Data represent mean +SEM (n = 3 to 7). * p < 0.05, ** p < 0.01; one-way ANOVA using Turkey-Kramer test.